Anda G.

Today we officially kick off our $2M pre seed round for Salubrum (Backed by Forum Ventures), supported by Forum Ventures, Coeus Collective Ventures, and Draper House Americas. Healthcare companies spend over $30B a year trying to acquire patients. The problem is not media. The problem is timing. Every time a patient approaches a healthcare decision a moment opens. Which doctor to see. Which procedure to pursue. Which treatment to start. For the companies involved in that decision, knowing that moment exists is incredibly valuable. Salubrum (Backed by Forum Ventures) is building the intelligence layer that maps those decision moments across the U.S. patient population. Our system aggregates large healthcare datasets covering 300M+ patient identities and uses them to predict when individuals are approaching important healthcare decisions. That signal can then be used by providers, pharma companies, payers, and other healthcare organizations trying to reach patients at the right time. Our first wedge is patient acquisition for healthcare providers and brands, but the underlying intelligence layer has much broader applications wherever patient behavior influences economic decisions. Over the past months we have quietly built the foundation. • Early pilots validating our patient intent scoring system • Distribution partnerships forming across healthcare platforms • Backed by Forum Ventures, Coeus Collective Ventures, Draper House Americas, NEXT Canada and Metta World Peace Starting tomorrow we will be meeting investors as part of the Forum Ventures showcase. If you are an investor interested in building with us get in touch. Calendly: https://lnkd.in/e5j-VvGC Investor Memo: https://lnkd.in/e5HyemAp

95

6 Comments

What do you do with a fresh $100m and dozens of the largest companies in the world as customers (The Coca-Cola Company, Novartis, Pfizer and all those other fancy logos, you know who you are!)? I'll tell you what ORO Labs does -- build AI agents on supply chain data ontologies which find problems fast, report real time spend, save literal 100s of millions of dollars, and super power procurement. Therefore your marketing leader in Brazil partners faster, your supply chain of chemicals components is more agile, your bankers buy the tech same day. The world moves faster. Simply said, ORO Labs is a marque examples of a system of record which is AI powering the largest companies in the world. The business is also run by the nicest and best of people. I'm so excited for Sudhir Bhojwani Lalitha Rajagopalan Yuan Tung and all of the team. So excited for this milestone and to be moving at speed.

30

1 Comment

Fundraising is one of the most misunderstood — and emotionally draining — parts of a founder’s journey. In my new Forbes column, I sat down with my friend Meirav Oren (Fainaru),who believes founders are not passengers in the fundraising journey — we are the pilots. Meirav is a seasoned entrepreneur, operator, advisor, and capital-raising strategist who has helped founders navigate some of the toughest markets in recent years. “The breakthrough moment came not only when I successfully navigated the journey for my own company, but when I began coaching a diverse range of founders to achieve the exact same breakthrough results. Meirav's work is especially relevant for U.S.-based founders navigating high-velocity raises in today’s market. Because nearly 80% of all venture dollars flow to companies headquartered in New York, California, and Massachusetts, the dynamics she describes map most directly to the U.S. ecosystem. That said, the framework is still valuable far beyond the U.S. — the principles of process, precision, and narrative clarity travel well, even if local contexts differ. If you’re building and fundraising — in the U.S. or beyond — this one is for you. Full piece below 👇 #Fundraising #Startups #Founders #Entrepreneurship #VentureCapital #StartupAdvice #FoundersJourney #StartupFundraising #Leadership #Forbes #WomenInBusiness #StartupTips

47

1 Comment

I met Craig Limoli, Founder and CEO of Wellsheet, in 2019. Craig was presenting at the Ai4 Healthcare Conference in New York City, hosted by Michael J Weiss . It was one of those early gatherings focused on AI in healthcare - well before the recent wave of hype. Craig took the stage to share how Wellsheet was using AI to help doctors and nurses make better, faster decisions at the point of care with its Care Team Copilot. Wellsheet’s technology was impressive, but its real edge came from Craig’s deep understanding of the problem he was solving. Before founding Wellsheet, he worked at IBM as a strategy consultant, helping large health systems assess their tech stacks. He saw firsthand that the tools available were clunky, fragmented, and ultimately failed to support the clinicians doing the hardest work. It’s a story as old as time - the very systems IBM was selling to hospitals weren’t meeting their actual needs. So, Craig left IBM, enrolled in the The Wharton School MBA program to sharpen his entrepreneurial skills, and decided to build the product those systems truly needed - a Care Team Copilot designed to summarize patient charts, streamline documentation, and support real-time collaboration between physicians and nurses. We stayed in touch after that first meeting, and a few months later, Wellsheet raised its $4.5 million Series A, which our team at SpringTide Ventures led. The round came together just as the world was shutting down in the early months of the pandemic. Understandably, Craig was nervous that investors might pull back as uncertainty swept through the market, but we didn’t. We believed in Wellsheet’s mission, and more importantly, in Craig’s ability to execute against it. Despite the chaos of 2020, he stayed focused and transparent - qualities that made us even more confident we were backing the right founder at the right time. Fast forward to today: Wellsheet is now live at hundreds of hospitals and continues to outperform much larger competitors. In fact, when a major national health system evaluated solutions from both Google and Wellsheet, they unanimously chose Wellsheet. The healthcare industry faces an unprecedented shortage of doctors, nurses, and frontline clinicians. Wellsheet’s technology helps address this challenge by automating the most time-consuming and manual parts of clinical work. For physicians, it means no more laborious data entry; for executives, it means decisions are queued up for them - clear, informed, and ready to act on. By streamlining chart reviews, documentation, and decision support, Wellsheet enables care teams to focus on what truly matters: delivering better patient outcomes. We’re proud to support, and keep championing founders like Craig and his mission-driven team at Wellsheet!

117

6 Comments

Midi Health just raised a $100M Series D and became the first menopause unicorn. This marks Actions Capital (fka K50 Ventures)'s ninth unicorn on the platform AND first investment for the Actions Growth Co-investment platform! We first met Joanna Strober in 2021 when we invested in the pre-seed, thanks to an intro from portfolio founder, Sarah Adler, PsyD (thanks Sarah!!). To me, the problem was staggering: 45 million women in the U.S. seeking care for menopause symptoms and not getting treatment, only 500 certified menopause providers in the entire country, 97% of midlife women without an OB/GYN, and an entire healthcare system that essentially told women to “tough it out”. Joanna had lived this problem herself, spending over a year searching for care, driving an hour to see a specialist, paying out of pocket, etc., and asked the question that would become Midi: Why isn't expert care for women at midlife easily accessible and covered by insurance? What started as a virtual care clinic has become the platform redefining how midlife women access healthcare in this country: • 25,000+ women receiving care every week. • Insurance-covered expert care in all 50 states. • Fortune 100 employers offering Midi as a health benefit. • Partnerships with major health systems and benefits providers nationwide. • Care that has expanded well beyond menopause into the full spectrum of midlife women's health. This $100M Series D round at $1B valuation was led by Goodwater Capital with Serena Ventures, Foresite Capital, and earlier investors including GV, Emerson Collective, SemperVirens, McKesson Ventures, AVP, and Felicis participating. Congrats to Joanna Strober, Sharon Meers, Jill Herzig, Kathleen Jordan, MD, Mindy Goldman, and the entire Midi Health team. You're no longer proving a concept. You're scaling a healthcare organization that women rely on every day. Let’s cook!

101

4 Comments

Founder: “It feels like everything is possible in AI right now.” Me (VC): “That’s true. And that’s exactly what makes this moment tricky.” Investing in pre-seed Israeli AI startups never felt more exciting or more disorienting... At Remagine Ventures, we’re falling in love with ideas at an unprecedented rate. - Companies are adopting new tools, enabling young startups to get traction - Models are improving monthly. Tooling is cheap. - It genuinely feels like the entire market is up for grabs. But beneath the excitement, there are real headwinds. - OpenAI reportedly ran at an ~$8B loss in 2025, with some predicting insolvency by 2027. It needs massive funding to keep the lights on - VC funding hit record highs, but AI now takes half of all VC dollars (which is increasingly concentrated in mega-deals) - Enterprise pilot → paid conversion sits at just 12% (McKinsey & Company, 2025) So while it feels like everything is possible, not everything is viable. If we're realistic, most AI startups will fall in one of these buckets: - Some companies will build enduring businesses - Some will find strong strategic buyers - Many will struggle quietly as economics, competition, and buyer expectations catch up. At pre-seed, the hardest part isn’t spotting what’s impressive. It’s spotting what’s resilient: 1) real wedges, not demos 2) painful problems, not cool tech 3) credible paths to distribution, not just early usage 4) founders who can navigate model shifts, pricing pressure, and buyer fatigue 5) a reinforcement learning advantage - the more data we get, the better the product becomes So when a founder tells me “everything is possible,” my next question is usually: What makes this company one that can last when the excitement fades? Pictured: an AI photoshoot with Chewbacca

36

10 Comments

I’m so proud that Hyphen Capital has been a backer of Tim Hwang and Jonathan Chen since the beginning of Nitra. They had big ambitions to modernize the archaic back office of healthcare practices from fax machines to AI. It’s been amazing to see their growth from processing zero transactions to over a billion dollars and they’re just getting started.

40

3 Comments

How AI Makes Medicine More Humane: An Analysis by Chatfuel CEO A new article from Fedor Pak, CEO of our portfolio company Chatfuel, has been published. Pavel wrote a column in MedCity News about how AI is transforming patient interactions in clinics. Key points from the article worth taking note of: ▪️ AI shouldn't replace doctors; it should assist. Medical clinics don't need an "all-knowing digital doctor." A much more useful tool is a "polite assistant with maximum functionality," who reminds patients about appointments 24/7, forwards instructions, answers common questions, and helps with scheduling. ▪️ Time savings and revenue growth. In real-world cases, communication automation allows clinics to process 3-5 times more requests without hiring new staff, reduces the number of patients who don't show up for appointments without warning by up to 45%, and increases the volume of paid procedures by 20-40% per week. ▪️ Automation makes clinics more humane. Doctors spend an average of almost 6 hours maintaining electronic medical records for every 8 hours they spend seeing patients. When AI takes over routine tasks, doctors arrive at their appointments less burned out and more focused. ▪️ It's not just about chatbots; communication automation is just the first step. AI support for clinical decision-making, predictive follow-ups, automated documentation, and more innovative anamnesis collection processes will follow. If you work in HealthTech or clinics, I recommend reading the entire article. It's an efficient and insightful look at the implementation of AI in healthcare. 🔗 Read the article on MedCity News: https://lnkd.in/eW8Nr-s6

19

My review of Pablos Holman's seriously probing (yet occasionally witty) book, Deep Future, about the core technologies that can transform key industries, in CTech by Calcalist. A must-read for any DeepTech investor or entrepreneur.

16

1 Comment

"𝗜𝘁 𝗼𝗻𝗹𝘆 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 𝗶𝗳 𝗶𝘁 𝗰𝗮𝗻 𝗯𝗲 𝘀𝗼𝗹𝗱!" This bold proclamation came from Neetu R., former CTO of Oscar Health and now Co-Founder/CEO of Lilac Software, at Primary Venture Partners ' Fall 2024 "On the Business" event. Truer words have never been spoken. While board members are certainly interested in learning about new product features, the roadmap, enhanced demos, etc., none of that work matters if it does not yield adoption and revenue. Product and technical teams MUST be thinking about the P&L implications just the same as their commercial counterparts. A simple table like the one below is sufficient (even better: include targets!), and should be supplemented with qualitative context. In this example, the sales team is doing good work selling the predictions and advanced analytics products to 𝘯𝘦𝘸 customers, but there is still an opportunity to do better with existing customers. The mobile app product may be new, which 𝘮𝘪𝘨𝘩𝘵 explain why penetration is still low, but it would be helpful to articulate both a forward-looking target and gameplan for how the company will get there. Even if you're not selling the new products you ship as separate SKUs (with the thought that they are protecting gross dollar retention), there must be accountability around adoption. In fact, this reality is arguably even 𝘮𝘰𝘳𝘦 important when you aren't monetizing.

25

3 Comments